Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$325.28 USD

325.28
1,978,129

+3.37 (1.05%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $325.29 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q4 Earnings?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright

AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull

Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.

Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 13.39% and 0.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.

Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings

Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".

What's in the Cards for Amgen (AMGN) This Earnings Season?

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.

Microsoft (MSFT) Q2 Earnings Beat, Azure & Gaming Aid Top Line

Microsoft's (MSFT) fiscal second-quarter results benefit from momentum in Azure, impressive Teams user growth led by work-from-home wave and solid uptake of new Xbox consoles.

Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer

The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.

Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

Sheraz Mian headshot

Top Stock Reports for NIKE, Amgen & Morgan Stanley

Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).

Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod

Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction

Why Amgen (AMGN) Could Beat Earnings Estimates Again

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.

Stock Market News for Jan 11, 2021

Benchmarks hit fresh record highs on Friday as President-elect Joe Biden promised new fiscal aid following a weak December jobs data.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies

AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.

Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.

AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies

AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.

Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

Mark Vickery headshot

Top Analyst Reports for Microsoft, Procter & Gamble & QUALCOMM

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Procter & Gamble (PG), and QUALCOMM (QCOM).